Tirzepatide

This product is synthesized and distributed exclusively for in vitro laboratory experimentation and in vivo animal research models. It is strictly NOT intended for human consumption, diagnostic procedures, or therapeutic use. All handling, reconstitution, and deployment must be conducted by qualified laboratory professionals using proper personal protective equipment.

Overview

Tirzepatide is a synthetic, long-acting peptide engineered as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. As the first investigational peptide designed to activate both incretin pathways simultaneously, Tirzepatide has become an important research tool for studying metabolic regulation, endocrine signalling, and receptor interactions.

Its dual receptor activity enables researchers to investigate the physiological effects of coordinated GIP and GLP-1 receptor activation on glucose metabolism, insulin signalling, energy balance, appetite regulation, lipid metabolism, and cardiometabolic physiology in both cellular systems and preclinical animal models. Tirzepatide has been extensively evaluated in large-scale clinical research programmes investigating obesity and type 2 diabetes, contributing substantially to the understanding of incretin biology.

Key Research Applications

Dual Incretin Receptor Pharmacology

Widely utilized to investigate the combined activation of GIP and GLP-1 receptors, enabling detailed evaluation of integrated incretin signalling pathways involved in metabolic homeostasis.

Glucose Metabolism

Studied in experimental models to evaluate receptor-mediated regulation of glucose homeostasis, pancreatic β-cell function, insulin secretion, glucagon modulation, and insulin sensitivity.

Energy Homeostasis

Applied in laboratory research examining mechanisms involved in energy expenditure, nutrient utilization, appetite regulation, and metabolic adaptation through dual incretin receptor signalling.

Adipose Tissue Biology

Investigated for its influence on adipocyte physiology, lipid metabolism, adipose tissue remodelling, and cellular pathways associated with energy storage and utilization.

Hepatic Metabolism

Researched to evaluate effects on hepatic glucose production, lipid metabolism, insulin responsiveness, and metabolic signalling within liver tissue models.

Cardiometabolic Research

Utilized in preclinical studies exploring biomarkers associated with cardiovascular physiology, inflammation, lipid metabolism, endothelial function, and overall metabolic health.

Technical Specifications

Classification: Dual GIP/GLP-1 Receptor Agonist

Peptide Type: Synthetic Long-Acting Incretin Mimetic

Receptor Targets: Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR); Glucagon-Like Peptide-1 Receptor (GLP-1R)

Appearance: White to off-white lyophilized powder

Purity: ≥98% (HPLC)

Solubility: Water-soluble following appropriate laboratory reconstitution procedures

Scientific References & Literature Citations

Discovery & Pharmacology

Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 385, 503–515. Supported the pharmacological characterization of dual GIP/GLP-1 receptor agonism.

Obesity Research

Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 387, 205–216. Demonstrated extensive investigation of tirzepatide in obesity research.

Garvey, W. T., et al. (2023). Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity (SURMOUNT-3). Nature Medicine, 29, 2909–2918. 

Technical Documentation Notice

This material is supplied exclusively for laboratory research purposes. For validated technical information regarding dual incretin receptor agonists, GLP-1 and GIP receptor pharmacology, endocrine signalling pathways, and metabolic research applications, investigators are encouraged to consult peer-reviewed scientific literature and established biomedical databases, including PubMed/NCBI, using the primary publications referenced above.

For Research Use Only (RUO). Not for human consumption, veterinary use, clinical application, or diagnostic procedures.